Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News BioXcel Therapeutics Inc BTAI

BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.... see more

Current News (NDAQ:BTAI)

BioXcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for IGALMI® in the At-Home Setting

GlobeNewswire 3 days ago

BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMI® Label Expansion in the At-Home Setting

GlobeNewswire January 20, 2026

Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Business Wire January 15, 2026

BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting

GlobeNewswire January 12, 2026

BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI®

GlobeNewswire January 7, 2026

Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions

GlobeNewswire December 3, 2025

BioXcel Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on Late-Stage Clinical Programs for Agitation in Bipolar, Schizophrenia, and Alzheimer's Disease

GlobeNewswire November 12, 2025

Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Business Wire October 24, 2025

BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes

GlobeNewswire October 14, 2025

Bullboard Posts (NDAQ:BTAI)

Buy buddy buy.

Otherwise FOMO for you fellas out there today anyway so good luck to all of you guys
coolfooldumbguy - August 27, 2025

Buy buddy buy because it's taking off this morning.

Otherwise FOMO for you fellas out there today anyway
coolfooldumbguy - August 18, 2025

RE:BTAI.....Too much volume ...not enough

Lulled me into submission
Iseneschal - August 5, 2025

BTAI.....Too much volume ...not enough

Price action No position
Iseneschal - August 4, 2025

BTAI....huge volume last FRiday & it's continuing this a.m

On watch at $1.75
Iseneschal - August 4, 2025

Using technical analysis for this stock.

BUY buddy buy because it's going up big-time and it's FOMO time for you fellas out there
coolfooldumbguy - August 4, 2025